Two antibody‐based PCSK9 inhibitors have been successfully developed for clinical use, proving effective in lowering cholesterol levels and reducing the risk of ASCVD events, including myocardial infarction, stroke, and death, without significant adverse effects [22]. This evidence concerns the gene PCSK9 and atherosclerosis.